气球可扩展的三年结果:20毫米与较大的 (≥23毫米) 相比
Marvin H Eng1, Houman Khalili2, John Vavalle3
1Banner University Medical Center-Phoenix, Phoenix, Arizona, USA.
JACC. Cardiovascular interventions
|August 23, 2024
概括
小型 (20毫米) 气球可扩展 (BEV) 的3年生存率与较大的 (≥23毫米) BEV相似. 然而,低平均梯度和严重的假肢患者不匹配与更糟糕的结果有关.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 人造心脏门是一种假心脏门.
背景情况:
- 之前的分析显示,小型 (20毫米) 与大型 (≥23毫米) 气球可扩展 (BEV) 的1年结果相似.
- 中期结果和假肢-患者不匹配 (PPM) 的影响需要进一步调查.
研究的目的:
- 评估小型与大型BEV的3年临床结果.
- 评估放电回声心脏学平均梯度 (MG) 和PPM定义与临床结果之间的关系.
主要方法:
- 从TVT注册表中对8,100对接受20毫米或≥23毫米BEV的患者进行倾向匹配分析.
- 卡普兰-梅尔图和调整的危险比率 (HRs) 用于分析MG和3年死亡率之间的关系.
主要成果:
- 在20毫米和≥23毫米的BEV组之间,3年死亡率没有显著差异 (31.5%对32.5%).
- 平均梯度 (MG) <10 mm Hg与3年死亡率增加有关 (HR: 1.25).
- 严重测量PPM和预测没有PPM与增加的死亡率有关;低MG和严重测量PPM与左下心室喷射率 (LVEF) 相相关.
结论:
- 小BEV (20毫米) 与较大的BEV (≥23毫米) 相比,显示出相当于3年生存率.
- 测量严重的PPM和低MG (<10毫米血) 与死亡率增加和较低的LVEF有关.
- 这些发现表明,LVEF在与PPM相关的不良结果中起着至关重要的作用.
更多相关视频
09:57Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
Published on: January 20, 2022
2.6K
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
2.8K
相关概念视频
Mitral Valve Prolapse III: Nursing Management
594
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
594
Mitral Regurgitation III: Medical Management
691
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
691
Mitral Stenosis III: Medical Management
539
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
539
Aortic Regurgitation III: Medical Management
599
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
599
Aneurysm III: Interprofessional Care
479
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
479
